comparative effectiveness

Research in Review

TKI Drug Improves Survival in Metastatic Kidney Cancer

11/22/2016

JCP Editors

First-line therapy with cabozantinib was superior to standard of care sunitinib with respect to progression-free survival and objective response rate for patients with intermediate- or poor-risk metastatic renal cell...

...

11/22/2016

Journal of Clinical Pathways

Research in Review

Robot-Assisted Radical Prostatectomy Leads to Greater Treatment-Free Survival Than Open Radical Prostatectomy

11/15/2016

JCP Editors

Robot-assisted radical prostatectomy (RARP) has comparable health outcomes and fewer associated adverse events than open radical prostatectomy (ORP), according to results published in the Journal of...

...

11/15/2016

Journal of Clinical Pathways

Research in Review

Analysis Finds Tocilizumab Superior to Conventional DMARDs in RA

11/15/2016

JCP Editors

A comparative effectiveness analysis of biologics for rheumatoid arthritis (RA) showed that tocilizumab monotherapy and tocilizumab plus methotrexate were superior to conventional disease-modifying antirheumatic...

A...

11/15/2016

Journal of Clinical Pathways

Research in Review

Pembrolizumab Better Than Chemotherapy for Urothelial Cancer

11/14/2016

JCP Editors

An anti-PD-1 therapy significantly improves overall survival (OS) compared with chemotherapy in previously treated patients with advanced bladder (urothelial) cancer, according to a study presented at the Society for...

An...

11/14/2016

Journal of Clinical Pathways

Research in Review

PD-1 Inhibitors Best Targeted Therapy for Advanced Melanoma

11/08/2016

JCP Editors

A combination of immunotherapy treatments improves survival and lowers the risk of life-threatening events for patients with late-stage melanoma compared with targeted therapy, according to a new JAMA Oncology...

A...

11/08/2016

Journal of Clinical Pathways

Research in Review

Treatment With Chemotherapy Drives Urothelial Cancer Resistance

10/21/2016

JCP Editors

Most patients with metastatic urothelial cancer will become resistant to therapy. New research published in Nature Genetics showed that chemotherapy also shapes the genetic evolution of remaining urothelial cancer...

Most...

10/21/2016

Journal of Clinical Pathways

Research in Review

Non-TNF Agents Show Promise for Patients With Inadequate RA Response

09/30/2016

JCP Editors

Patients with rheumatoid arthritis (RA) previously treated to a first-line anti-tumor necrosis factor (TNF) drug who have an inadequate response may experience a better outcome with a non-TNF biologic agent than with...

...

09/30/2016

Journal of Clinical Pathways

Department

Hypofractionated Radiation Therapy Safer, Halves Treatment Time in NSCLC

09/27/2016

JCP Editors

Hypofractionated radiation therapy is less toxic and just as effective as conventional radiation therapy in patients with non-small cell lung cancer (NSCLC), according to research presented at the 58th Annual Meeting...

...

09/27/2016

Journal of Clinical Pathways

Quiz

Friday Morning Quiz: Week of Aug 29-Sept 4

09/01/2016

JCP Editors

A study published in JAMA Oncology found that increasing the number of treatment cycles with what drug led to improved overall survival in men with metastatic castration-resistant prostate...

A...

09/01/2016

Journal of Clinical Pathways

Research in Review

More Chemotherapy Does Not Lead to Improved Outcomes for Patients With Osteosarcoma

08/31/2016

JCP Editors

Results from a large clinical trial argue against the inclusion of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly responding osteosarcoma due to increasing toxicity and no improvement...

...

08/31/2016

Journal of Clinical Pathways